Go Deep
Immuno-Biological Laboratories Co., Ltd.
Immuno-Biological Laboratories Co., Ltd. Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | 22,919 | 26.1 | 5.21 | 0.09 | 624.74 |
Immuno-Biological Laboratories Co., Ltd. Quarterly Results
| Line Item | Jun 2026 | Jun 2025 |
|---|---|---|
| EPS | 10.8 | 6.5 |
Immuno-Biological Laboratories Co., Ltd. Revenue & Profit: Last 5 Years
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Revenue | 1,004,987,000.0 | 969,533,000.0 | 816,701,000.0 | 794,621,000.0 | — |
| Net Profit | 329,015,000.0 | 249,047,000.0 | 186,694,000.0 | -289,731,000.0 | — |
| EPS | 35.3 | 26.7 | 20.1 | -31.1 | — |
Immuno-Biological Laboratories Co., Ltd. Balance Sheet
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Total Assets | 2,155,121,000.0 | 1,845,390,000.0 | 1,618,582,000.0 | 1,434,337,000.0 | — |
| Total Liabilities | 311,747,000.0 | 331,031,000.0 | 353,271,000.0 | 355,721,000.0 | — |
| Total Equity | 1,843,374,000.0 | 1,514,359,000.0 | 1,265,311,000.0 | 1,078,616,000.0 | — |
Owes vs Owns
Immuno-Biological Laboratories Co., Ltd. owed ¥0.14 for every ¥1 it owned in Mar 2026, down from ¥0.25 in Mar 2023.
| Period | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Owes vs Owns | 0.14× | 0.18× | 0.22× | 0.25× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
Immuno-Biological Laboratories Co., Ltd. Assets & Liabilities Breakdown (JPY millions)
What it owns — Mar 2026
Cash & short-term investments 45.9%Receivables 8.3%Inventory 17.6%Fixed assets (tangible) 9.9%Long-term investments 7.9%Other assets 10.3%
How it's funded — Mar 2026
Short-term debt 7.4%Long-term debt 0.9%Other liabilities 6.1%Shareholders' equity 85.5%
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 989.5 | 825.7 | 734.1 | 614.2 |
| Receivables | 178.7 | 231.5 | 190.3 | 223.0 |
| Inventory | 379.7 | 317.8 | 321.9 | 318.0 |
| Fixed assets (tangible) | 213.2 | 191.1 | 135.8 | 119.3 |
| Intangible assets | 1.3 | 1.8 | 2.3 | 0.0 |
| Long-term investments | 170.1 | 95.1 | 95.1 | 95.2 |
| Other assets | 222.7 | 182.4 | 139.1 | 64.6 |
| Liabilities & equity | ||||
| Short-term debt | 158.4 | 169.1 | 151.4 | 135.9 |
| Long-term debt | 18.7 | 35.1 | 84.6 | 99.1 |
| Payables | 3.0 | 3.7 | 4.3 | 5.7 |
| Other liabilities | 131.7 | 123.1 | 112.9 | 115.0 |
| Shareholders' equity | 1,843.4 | 1,514.4 | 1,265.3 | 1,078.6 |
| Net tangible assets | 1,842.1 | 1,512.6 | 1,263.0 | 1,078.6 |
Immuno-Biological Laboratories Co., Ltd. Cash Flow
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Operating Activities | 301,093,000.0 | 183,495,000.0 | 133,775,000.0 | 26,458,000.0 | — |
| Investing Activities | -116,463,000.0 | -53,660,000.0 | -24,496,000.0 | 30,036,000.0 | — |
| Financing Activities | -27,136,000.0 | -31,755,000.0 | 991,000.0 | 991,000.0 | — |